dr holst glp 1 Exclusive interview: Jens Juul GLP-1 weight loss discoverers win

Oprah and Bren recently got together to talk about Browns #1 bestseller, Atlas of the Heart.

The results prompt safety concerns for GLP-1RAs, especially with high dose administration, regarding gastrointestinal adverse events

Support your GLP-1 journey with a high-protein meal plan + expert tips to reduce side effects and protect muscle

A new study unmasks a genetic defect in the Nav1.8 ion channel that drives chronic hyperhidrosis.

Last week, Eli Lillys orforglipron has become the first oral, non-peptide GLP-1 receptor agonist to clear a Phase 3 trial, showing strong efficacy in reducing A1C (up to 1.6%) and body weight (up to 7.9%) in people with type 2 diabetes

While the regulator has not approved their use in type 1 diabetes, off-label prescribing for GLP-1 receptor agonists has sharply increased, according to researchers, who warn about the risk of serious side effects such as ketoacidosis.